Alexion Pharmaceuticals (ALXN) PT Cut to $140 at Jefferies on Future Soliris Competition
Tweet Send to a Friend
Jefferies analyst Eun Yang reiterated a Hold rating and lowered its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $140.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
